Aclaris Therapeutics Stock Today
| ACRS Stock | USD 1.57 0.02 1.29% |
PerformanceVery Weak
| Odds Of DistressQuite High
|
Aclaris Therapeutics is selling for under 1.57 as of the 21st of March 2025; that is 1.29 percent increase since the beginning of the trading day. The stock's lowest day price was 1.55. Aclaris Therapeutics has more than 69 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of October 2015 | Category Healthcare | Classification Health Care |
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 108.15 M outstanding shares of which 5.02 M shares are presently shorted by private and institutional investors with about 7.08 trading days to cover. More on Aclaris Therapeutics
Moving together with Aclaris Stock
Moving against Aclaris Stock
| 0.34 | PFE | Pfizer Inc Sell-off Trend | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Aclaris Stock Highlights
| President, CoFounder | Neal DO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite Total, Health Care, Pharmaceuticals, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAclaris Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aclaris Therapeutics' financial leverage. It provides some insight into what part of Aclaris Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aclaris Therapeutics (ACRS) is traded on NASDAQ Exchange in USA. It is located in 701 Lee Road, Wayne, PA, United States, 19087 and employs 61 people. Aclaris Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 167.63 M. Aclaris Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 108.15 M outstanding shares of which 5.02 M shares are presently shorted by private and institutional investors with about 7.08 trading days to cover.
Aclaris Therapeutics currently holds about 248.6 M in cash with (20.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Aclaris Therapeutics Probability Of Bankruptcy
Ownership AllocationAclaris Therapeutics holds a total of 108.15 Million outstanding shares. The majority of Aclaris Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aclaris Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aclaris Therapeutics. Please pay attention to any change in the institutional holdings of Aclaris Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Aclaris Ownership Details
Aclaris Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Logos Global Management Lp | 2024-12-31 | 2.2 M | |
| Millennium Management Llc | 2024-12-31 | 2 M | |
| Blackrock Inc | 2024-12-31 | 1.3 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.1 M | |
| Aldebaran Capital Llc | 2024-12-31 | 1 M | |
| Two Sigma Advisers, Llc | 2024-12-31 | 977.4 K | |
| Deutsche Bank Ag | 2024-12-31 | 923.3 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 908.8 K | |
| Monashee Investment Management Llc | 2024-12-31 | 888.9 K | |
| Bml Capital Management Llc | 2024-12-31 | 14.2 M | |
| Adage Capital Partners Gp Llc | 2024-12-31 | 9.6 M |
Aclaris Therapeutics Historical Income Statement
Aclaris Stock Against Markets
Aclaris Therapeutics Corporate Executives
Elected by the shareholders, the Aclaris Therapeutics' board of directors comprises two types of representatives: Aclaris Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aclaris. The board's role is to monitor Aclaris Therapeutics' management team and ensure that shareholders' interests are well served. Aclaris Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aclaris Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Ruffo | CFO CoFounder | Profile |
Already Invested in Aclaris Therapeutics?
The danger of trading Aclaris Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aclaris Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aclaris Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aclaris Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.